<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00932477</url>
  </required_header>
  <id_info>
    <org_study_id>AG9965-001</org_study_id>
    <nct_id>NCT00932477</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Artificial Tears in Dry Eye Subjects</brief_title>
  <official_title>Safety and Tolerability of Artificial Tears in Dry Eye Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety and tolerability of two new artificial tears will be compared to a
      currently-available artificial tear in subjects with dry eye. Each subject will receive all
      three products in a randomly assigned order. The subject will use one product at a time for a
      duration of one week before switching to the next assigned product.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability Questionnaire Mean Scores at 1 Week</measure>
    <time_frame>1 Week</time_frame>
    <description>Tolerability Questionnaire mean scores at 1 week. The Tolerability Questionnaire includes 8 tolerability questions on selected performance measures. All questions are scored based on continuous visual analog scale from 0-100. The first 4 questions presented measure increasing tolerability where 0=worst and 100=best. The second set of 4 questions presented measure decreasing tolerability where 0=best and 100=worst.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least One Severity Grade Increase in Biomicroscopy Findings at 1 Week</measure>
    <time_frame>1 Week</time_frame>
    <description>Number of patients with at least one severity grade increase in biomicroscopy findings at 1 week. Eyes are examined with a special microscope (biomicroscopy), and findings scored using a 5-point scale (0=none, +0.5=trace, +1=mild, +2=moderate, +3=severe). An increase in severity grade indicates worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best-Corrected Visual Acuity (BCVA) Status at 1 Week</measure>
    <time_frame>1 Week</time_frame>
    <description>BCVA status at 1 week reported as the number of patients whose scores were either &quot;Better&quot;, &quot;No Change&quot;, or &quot;Worse&quot; than their scores at baseline. The status was tabulated as number of lines read correctly at 1 week minus the number of lines read correctly at baseline. &quot;Better&quot; equals increase of 2 lines or more in at least 1 eye; &quot;No Change&quot; equals change between -2 to +2 lines in either eye; &quot;Worse&quot; equals decrease of 2 lines or more in at least 1 eye. BCVA is measured using a special eye chart and is reported as the number of lines (5 letters per line) read correctly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Ophthalmic Adverse Events at 1 Week</measure>
    <time_frame>1 Week</time_frame>
    <description>The number of ophthalmic adverse events (AE) at 1 week. An ophthalmic AE is any unfavorable and unintended sign, symptom, or disease related to the eye which occurs during the use of the study investigational product</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>Artificial Tear Formulation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artificial Tear Formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glycerin and Polysorbate 80 based artificial tear</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glycerin and Polysorbate 80 based artificial tear</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear</intervention_name>
    <description>1 to 2 drops into each eye three times per day</description>
    <arm_group_label>Artificial Tear Formulation 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear</intervention_name>
    <description>1 to 2 drops into each eye three times per day</description>
    <arm_group_label>Artificial Tear Formulation 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycerin and Polysorbate 80 based artificial tear</intervention_name>
    <description>1 to 2 drops into each eye three times per day</description>
    <arm_group_label>Glycerin and Polysorbate 80 based artificial tear</arm_group_label>
    <other_name>Refresh Dry Eye TherapyÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild, moderate or severe symptoms of dry eye

        Exclusion Criteria:

          -  Uncontrolled systemic disease

          -  Contact lens wear

          -  Participation in another clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2009</study_first_submitted>
  <study_first_submitted_qc>July 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2009</study_first_posted>
  <results_first_submitted>November 9, 2011</results_first_submitted>
  <results_first_submitted_qc>November 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2011</results_first_posted>
  <last_update_submitted>August 17, 2015</last_update_submitted>
  <last_update_submitted_qc>August 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycerol</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This is a 3-treatment, 3-period, 6-sequence crossover study. Each subject received all 3 products in a randomly assigned order. The subject used 1 product at a time for a duration of 1 week before switching to the next assigned product (e.g., with treatments A, B, and C, the sequences were ABC, ACB, BAC, BCA, CAB, and CBA).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence ABC</title>
          <description>Started with Treatment A: Artificial Tear Formulation 1 followed by Treatment B: Artificial Tear Formulation 2 followed by Treatment C: Glycerin and Polysorbate 80 based artificial tear</description>
        </group>
        <group group_id="P2">
          <title>Sequence ACB</title>
          <description>Started with Treatment A: Artificial Tear Formulation 1 followed by Treatment C: Glycerin and Polysorbate 80 based artificial tear followed by Treatment B: Artificial Tear Formulation 2</description>
        </group>
        <group group_id="P3">
          <title>Sequence BAC</title>
          <description>Started with Treatment B: Artificial Tear Formulation 2 followed by Treatment A: Artificial Tear Formulation 1 followed by Treatment C: Glycerin and Polysorbate 80 based artificial tear</description>
        </group>
        <group group_id="P4">
          <title>Sequence BCA</title>
          <description>Started with Treatment B: Artificial Tear Formulation 2 followed by Treatment C: Glycerin and Polysorbate 80 based artificial tear followed by Treatment A: Artificial Tear Formulation 1</description>
        </group>
        <group group_id="P5">
          <title>Sequence CAB</title>
          <description>Started with Treatment C: Glycerin and Polysorbate 80 based artificial tear followed by Treatment A: Artificial Tear Formulation 1 followed by Treatment B: Artificial Tear Formulation 2</description>
        </group>
        <group group_id="P6">
          <title>Sequence CBA</title>
          <description>Started with Treatment C: Glycerin and Polysorbate 80 based artificial tear followed by Treatment B: Artificial Tear Formulation 2 followed by Treatment A: Artificial Tear Formulation 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All Study Participants</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tolerability Questionnaire Mean Scores at 1 Week</title>
        <description>Tolerability Questionnaire mean scores at 1 week. The Tolerability Questionnaire includes 8 tolerability questions on selected performance measures. All questions are scored based on continuous visual analog scale from 0-100. The first 4 questions presented measure increasing tolerability where 0=worst and 100=best. The second set of 4 questions presented measure decreasing tolerability where 0=best and 100=worst.</description>
        <time_frame>1 Week</time_frame>
        <population>Safety population, which consisted of all patients who started the study (randomized) and received treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Artificial Tear Formulation 1</title>
            <description>Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear</description>
          </group>
          <group group_id="O2">
            <title>Artificial Tear Formulation 2</title>
            <description>Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear</description>
          </group>
          <group group_id="O3">
            <title>Glycerin and Polysorbate 80 Based Artificial Tear</title>
            <description>Glycerin and Polysorbate 80 based artificial tear</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability Questionnaire Mean Scores at 1 Week</title>
          <description>Tolerability Questionnaire mean scores at 1 week. The Tolerability Questionnaire includes 8 tolerability questions on selected performance measures. All questions are scored based on continuous visual analog scale from 0-100. The first 4 questions presented measure increasing tolerability where 0=worst and 100=best. The second set of 4 questions presented measure decreasing tolerability where 0=best and 100=worst.</description>
          <population>Safety population, which consisted of all patients who started the study (randomized) and received treatment.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>How comfortable is drop in the eye?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1" spread="30.01"/>
                    <measurement group_id="O2" value="70.7" spread="26.63"/>
                    <measurement group_id="O3" value="57.3" spread="31.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How soothing is drop in the eye?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.1" spread="31.67"/>
                    <measurement group_id="O2" value="65.9" spread="27.68"/>
                    <measurement group_id="O3" value="53.4" spread="32.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How moistening/lubricating is drop in the eye?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" spread="27.79"/>
                    <measurement group_id="O2" value="65.9" spread="28.41"/>
                    <measurement group_id="O3" value="57.4" spread="31.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How clear is vision with drop in the eye?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" spread="30.91"/>
                    <measurement group_id="O2" value="61.1" spread="30.78"/>
                    <measurement group_id="O3" value="53.0" spread="30.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How much stickiness with drop in the eye?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" spread="29.44"/>
                    <measurement group_id="O2" value="19.5" spread="23.82"/>
                    <measurement group_id="O3" value="31.4" spread="29.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How much blur with drop in the eye?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="29.88"/>
                    <measurement group_id="O2" value="32.4" spread="30.52"/>
                    <measurement group_id="O3" value="48.9" spread="30.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How much burning/stinging with drop in the eye?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="22.48"/>
                    <measurement group_id="O2" value="14.3" spread="22.40"/>
                    <measurement group_id="O3" value="27.9" spread="30.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How much discomfort with drop in the eye?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="24.84"/>
                    <measurement group_id="O2" value="18.9" spread="26.27"/>
                    <measurement group_id="O3" value="27.1" spread="28.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least One Severity Grade Increase in Biomicroscopy Findings at 1 Week</title>
        <description>Number of patients with at least one severity grade increase in biomicroscopy findings at 1 week. Eyes are examined with a special microscope (biomicroscopy), and findings scored using a 5-point scale (0=none, +0.5=trace, +1=mild, +2=moderate, +3=severe). An increase in severity grade indicates worsening.</description>
        <time_frame>1 Week</time_frame>
        <population>Safety population, which consisted of all patients who started the study (randomized) and received treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Artificial Tear Formulation 1</title>
            <description>Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear</description>
          </group>
          <group group_id="O2">
            <title>Artificial Tear Formulation 2</title>
            <description>Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear</description>
          </group>
          <group group_id="O3">
            <title>Glycerin and Polysorbate 80 Based Artificial Tear</title>
            <description>Glycerin and Polysorbate 80 based artificial tear</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least One Severity Grade Increase in Biomicroscopy Findings at 1 Week</title>
          <description>Number of patients with at least one severity grade increase in biomicroscopy findings at 1 week. Eyes are examined with a special microscope (biomicroscopy), and findings scored using a 5-point scale (0=none, +0.5=trace, +1=mild, +2=moderate, +3=severe). An increase in severity grade indicates worsening.</description>
          <population>Safety population, which consisted of all patients who started the study (randomized) and received treatment.</population>
          <units>Number of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pterygium (cornea)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Punctate keratitis (cornea)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vital dye staining of cornea present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best-Corrected Visual Acuity (BCVA) Status at 1 Week</title>
        <description>BCVA status at 1 week reported as the number of patients whose scores were either &quot;Better&quot;, &quot;No Change&quot;, or &quot;Worse&quot; than their scores at baseline. The status was tabulated as number of lines read correctly at 1 week minus the number of lines read correctly at baseline. &quot;Better&quot; equals increase of 2 lines or more in at least 1 eye; &quot;No Change&quot; equals change between -2 to +2 lines in either eye; &quot;Worse&quot; equals decrease of 2 lines or more in at least 1 eye. BCVA is measured using a special eye chart and is reported as the number of lines (5 letters per line) read correctly.</description>
        <time_frame>1 Week</time_frame>
        <population>Safety population, which consisted of all patients who started the study (randomized) and received treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Artificial Tear Formulation 1</title>
            <description>Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear</description>
          </group>
          <group group_id="O2">
            <title>Artificial Tear Formulation 2</title>
            <description>Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear</description>
          </group>
          <group group_id="O3">
            <title>Glycerin and Polysorbate 80 Based Artificial Tear</title>
            <description>Glycerin and Polysorbate 80 based artificial tear</description>
          </group>
        </group_list>
        <measure>
          <title>Best-Corrected Visual Acuity (BCVA) Status at 1 Week</title>
          <description>BCVA status at 1 week reported as the number of patients whose scores were either &quot;Better&quot;, &quot;No Change&quot;, or &quot;Worse&quot; than their scores at baseline. The status was tabulated as number of lines read correctly at 1 week minus the number of lines read correctly at baseline. &quot;Better&quot; equals increase of 2 lines or more in at least 1 eye; &quot;No Change&quot; equals change between -2 to +2 lines in either eye; &quot;Worse&quot; equals decrease of 2 lines or more in at least 1 eye. BCVA is measured using a special eye chart and is reported as the number of lines (5 letters per line) read correctly.</description>
          <population>Safety population, which consisted of all patients who started the study (randomized) and received treatment.</population>
          <units>Number of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Ophthalmic Adverse Events at 1 Week</title>
        <description>The number of ophthalmic adverse events (AE) at 1 week. An ophthalmic AE is any unfavorable and unintended sign, symptom, or disease related to the eye which occurs during the use of the study investigational product</description>
        <time_frame>1 Week</time_frame>
        <population>Safety population, which consisted of all patients who started the study (randomized) and received treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Artificial Tear Formulation 1</title>
            <description>Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear</description>
          </group>
          <group group_id="O2">
            <title>Artificial Tear Formulation 2</title>
            <description>Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear</description>
          </group>
          <group group_id="O3">
            <title>Glycerin and Polysorbate 80 Based Artificial Tear</title>
            <description>Glycerin and Polysorbate 80 based artificial tear</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Ophthalmic Adverse Events at 1 Week</title>
          <description>The number of ophthalmic adverse events (AE) at 1 week. An ophthalmic AE is any unfavorable and unintended sign, symptom, or disease related to the eye which occurs during the use of the study investigational product</description>
          <population>Safety population, which consisted of all patients who started the study (randomized) and received treatment.</population>
          <units>Number of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Eye pruritis (itching)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal sensation in eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (redness) of eyelid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eyelid irritation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Artificial Tear Formulation 1</title>
          <description>Formulation 1 Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80 based artificial tear</description>
        </group>
        <group group_id="E2">
          <title>Artificial Tear Formulation 2</title>
          <description>Formulation 2 Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80 based artificial tear</description>
        </group>
        <group group_id="E3">
          <title>Glycerin and Polysorbate 80 Based Artificial Tear</title>
          <description>Glycerin and Polysorbate 80 based artificial tear</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan, Inc.</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

